Allspring Global Investments Holdings LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 9.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,113,748 shares of the medical research company's stock after selling 115,810 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.84% of Natera worth $178,805,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of NTRA. Wellington Management Group LLP increased its holdings in Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after buying an additional 1,883,481 shares in the last quarter. PointState Capital LP boosted its position in Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock worth $99,343,000 after purchasing an additional 413,468 shares during the last quarter. Franklin Resources Inc. boosted its position in Natera by 42.6% in the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company's stock worth $144,958,000 after purchasing an additional 328,375 shares during the last quarter. ARK Investment Management LLC boosted its position in Natera by 65.6% in the third quarter. ARK Investment Management LLC now owns 687,703 shares of the medical research company's stock worth $87,304,000 after purchasing an additional 272,361 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its position in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock worth $170,119,000 after purchasing an additional 269,706 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on NTRA shares. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Canaccord Genuity Group raised their target price on Natera from $165.00 to $180.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler lifted their price objective on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus price target of $165.88.
Get Our Latest Analysis on Natera
Natera Price Performance
NASDAQ NTRA traded up $2.66 during trading hours on Friday, reaching $173.39. The company's stock had a trading volume of 1,571,626 shares, compared to its average volume of 1,326,767. The firm's 50-day moving average price is $167.75 and its 200-day moving average price is $142.83. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $68.03 and a 1 year high of $183.00. The company has a market capitalization of $22.89 billion, a price-to-earnings ratio of -98.52 and a beta of 1.66.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. During the same period in the previous year, the firm earned ($0.95) EPS. The firm's revenue was up 63.9% compared to the same quarter last year. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Insiders Place Their Bets
In other Natera news, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total value of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company's stock, valued at $207,135,977.44. The trade was a 6.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John Fesko sold 663 shares of Natera stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 305,454 shares of company stock valued at $51,290,625 in the last quarter. 7.60% of the stock is currently owned by insiders.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
